- Home
- RVT vs KROS Comparison
RVT vs KROS Comparison
Compare RVT & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVT
- KROS
- Stock Information
- Founded
- RVT 1986
- KROS 2015
- Country
- RVT United States
- KROS United States
- Employees
- RVT N/A
- KROS N/A
- Industry
- RVT Trusts Except Educational Religious and Charitable
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- RVT Finance
- KROS Health Care
- Exchange
- RVT Nasdaq
- KROS Nasdaq
- Market Cap
- RVT 1.7B
- KROS 1.8B
- IPO Year
- RVT N/A
- KROS 2020
- Fundamental
- Price
- RVT $16.22
- KROS $54.53
- Analyst Decision
- RVT
- KROS Strong Buy
- Analyst Count
- RVT 0
- KROS 8
- Target Price
- RVT N/A
- KROS $91.43
- AVG Volume (30 Days)
- RVT 243.4K
- KROS 406.0K
- Earning Date
- RVT 01-01-0001
- KROS 11-06-2024
- Dividend Yield
- RVT 7.32%
- KROS N/A
- EPS Growth
- RVT N/A
- KROS N/A
- EPS
- RVT 2.95
- KROS N/A
- Revenue
- RVT N/A
- KROS $651,000.00
- Revenue This Year
- RVT N/A
- KROS $1,232.45
- Revenue Next Year
- RVT N/A
- KROS $126.39
- P/E Ratio
- RVT $4.98
- KROS N/A
- Revenue Growth
- RVT N/A
- KROS 8037.50
- 52 Week Low
- RVT $11.85
- KROS $27.31
- 52 Week High
- RVT $14.93
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- RVT 54.19
- KROS 34.48
- Support Level
- RVT $15.72
- KROS $52.64
- Resistance Level
- RVT $16.93
- KROS $70.26
- Average True Range (ATR)
- RVT 0.28
- KROS 3.31
- MACD
- RVT -0.03
- KROS -1.44
- Stochastic Oscillator
- RVT 51.12
- KROS 4.88
About RVT Royce Value Trust Inc.
Royce Value Trust Inc is a diversified closed-end investment company. It invests in diversified sectors including consumer discretionary, consumer staples, healthcare, financial, IT, telecommunications, and materials. The company's portfolio includes common stocks, preferred stocks, corporate bonds, and repurchase agreements.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.